Maura O. Kahn
Vice President, Business Development & Marketing
O (443) 543-5783
NOXILIZER LICENSES TECHNOLOGY TO STG FOR KEY LIFE SCIENCE MARKET
STG to develop Noxilizer technology for global decontamination generator opportunities.
(Baltimore, MD and Cary, NC — June 22, 2011) Noxilizer, Inc. and Sterilization Technology Group, Inc. (STG) announced today an agreement to develop products for the isolator generator market. Noxilizer is licensing its proprietary nitrogen dioxide technology. STG will be responsible for the development, manufacturing and commercialization of this product line.
Isolators and other related enclosures are an important part of any life science company’s manufacturing and research and development process. The closed areas are used to produce products in a decontaminated environment. Examples of products include: prefilled syringes and insulin vials. Sterilant generators were developed in the late 1980’s to provide more effective decontamination. Today, the STERIS Corporation (Mentor, OH) and Skan AG (Switzerland) are the leading companies in the isolator decontamination generator market. Both companies utilize hydrogen peroxide.
“This licensing agreement further validates Noxilizer’s technology and its importance in solving challenges of infection control and decontamination. The Noxilizer team is excited to work with STG as we grow our business in the important isolator market,” says Lawrence Bruder, President & CEO of Noxilizer, Inc.
“As a 30-year veteran of this industry, I see real advantages that the Noxilizer technology has over the current process options. We believe customers will value the faster aeration time and improved material compatibility,” states Michael Ferguson, Business Director of STG.
A sterilant generator is in the development stage and will go through additional testing this year. Potential customers include: pharmaceutical and biotech companies, research and development, manufacturing and quality control groups.
About Noxilizer, Inc.:
Noxilizer has developed a unique and superior sterilization technology that will revolutionize two major sterilization markets — hospitals and life science manufacturing. In hospitals, Noxilizer is developing a system especially for the sensitive, high-tech equipment increasingly used in minimally-invasive surgical procedures. In the life science market, Noxilizer provides sterilization services for next generation therapies and medical devices. The company was founded in 2004 and is privately held. Noxilizer is located at the University of Maryland Baltimore County Technology Center in Baltimore, MD.
About Sterilization Technology Group, Inc. (STG):
STG was formed in 2006 to develop and market a superior method for decontamination of sealed enclosures for the pharmaceutical and biotechnology markets. The founders of STG have over 70 years of combined experience in developing novel technologies and in the validation of processes for FDA compliance in this industry. STG is designing and developing products that will surpass all current technologies with regard to aeration and cycle times without sacrificing microbiological kill rates or materials compatibility. STG feels the industry is looking for a “next generation” product to replace existing technologies that have not changed in over 20 years. STG is located in Cary, North Carolina with manufacturing in Wisconsin.